Analyst Brandon Folkes of H.C. Wainwright reiterated a Buy rating on ANI Pharmaceuticals, retaining the price target of $121.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight ANI Pharmaceuticals’ strong commercial execution capabilities and promising growth prospects. The company’s impressive performance in the third quarter of 2025, particularly with Cortrophin Gel, underscores its potential. Cortrophin Gel’s revenue exceeded expectations, driven by significant year-on-year growth and increased new patient starts across multiple specialties. This success is attributed to the expanded sales force and the product’s unique positioning as the only approved ACTH therapy for acute gouty arthritis flares.
Additionally, ANI Pharmaceuticals’ diversified business model and the strategic expansion of the Cortrophin sales team provide the company with financial flexibility to further invest in its growth. Despite some challenges with ILUVIEN, the company anticipates a return to growth, supported by increased clinical visibility and adoption for new indications. These factors collectively reinforce the Buy rating, as they demonstrate ANI Pharmaceuticals’ robust market position and future growth potential.
In another report released on October 27, Guggenheim also reiterated a Buy rating on the stock with a $114.00 price target.